Kleberg Foundation

August 30, 2022

A new mechanism for lupus

Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.

By Leigh MacMillan
February 4, 2021

Gene network for leukemia factor

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.

By Leigh MacMillan
January 21, 2021

WIN for blocking cancer growth

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.

By Sarah E. Glass
Lymphocytes attacking cancer cell
August 31, 2017

Pancreatic cancer development

Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.

By Leigh MacMillan
August 3, 2017

HDAC3 role in B-cell development

The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.

By Leigh MacMillan
June 14, 2017

PET imaging to predict tumor response

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

By Leigh MacMillan
February 9, 2017

New grants bolster Trauma program’s research initiatives

Vanderbilt University Medical Center’s Division of Trauma, Emergency General Surgery and Surgical Critical Care was recently awarded two new research grants.
By VUMC News and Communications
August 3, 2016

Kleberg Foundation grant bolsters cancer drug discovery efforts

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”
By VUMC News and Communications
December 10, 2015

New lead for ovarian cancer treatment

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer.
By VUMC News and Communications
August 14, 2014

Growth factor blockade targets breast tumors

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
By VUMC News and Communications
May 8, 2014

PET probe detects dying tumor cells

A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.
By Leigh MacMillan